Delay in consultation and starting disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis. How early arthritis clinics impact on health barriers?

Natalia Zamora1, Christian A. Waimann1, Maria Florencia Marengo1, Gustavo Citera1, Amelia Granel2, Ana Iné’s Marcos2, Emilio Buschiazzo3, Ricardo V. Juarez3, Dora Pereira4, Gisela Pendo´n4, Andrea D’Orazio5, Mariana Salcedo6, Judith Sarano7, Marí´a Victoria Collado7, Graciela Go´mez7, Alejandra Medina8, Marí´a Eugenia Lara9, Juan C. Barreira9, Marí´a Alicia La´zaro10, Alejandra Cusa10, Luciana Gonza´lez Lucero11, Marí´a Silvia Yacuzzi11, Rau´l Nicolas Martínez11 and Pablo Arturi12. 1Instituto de Rehabilitacio´n Psicofı´sica, Buenos Aires, Argentina, 2Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, 3HospitalSan´or del Milagro, Salta, Argentina, 4Hospital Ricardo Gutierrez, La Plata, La Plata, Argentina, 5Hospital de la Asociacion Medica de Bahı´a Blanca, Bahı´a Blanca, Argentina, 6Consultorio Privado, San Nicola’s, Argentina, 7Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, 8Hospital General de Agudos “Dr. E. Tornu”, Ciudad Auto´noma de Buenos Aires, Argentina, 9Buenos Aires British Hospital, Buenos Aires, Argentina, 10Hospital central de San isidro Dr A. Posse, San Isidro, Argentina, 11Hospital Angel C. Padilla de San Miguel de Tucumá´n, San Miguel de Tucumá´n, Argentina, 12Hospital Italiano de La Plata, La Plat a, Argentina.

Background: An early and aggressive treatment has become the cornerstone in the treatment of Rheumatoid Arthritis (RA). For this reason, an early consult with a rheumatologist is crucial. The aim of our study was to evaluate the delay in consultation and starting disease modifying anti-rheumatic drugs (DMARDs) in patients with RA, and to assess the impact of early arthritis clinics and health barriers on such delay.

Material and Methods: We carried out a multicenter study including patients with a diagnosis of RA of less than 5 years of disease duration. Data collected included clinical, economic, sociodemographic characteristics, health insurance and health care center (private vs. public hospital; early arthritis clinics vs. routine care hospitals). In addition, we evaluated the presence of health barriers in those patients with <2 years of disease duration, including geographical location, social support, family and work responsibilities, economics issues, accessibility to health care, self-treatment, patient-physician relationship. Three time-points were evaluated: time to first medical contact, time to rheumatologist and time to initiation of first DMARD. The association between variables and time-points were assessed using univariate and multivariate models.

Results: A total of 316 patients were included; 86% were female, mean age was 47 ± 14 years, disease duration 7 ± 5 years, 73% had low income (less than ≈ 1000 dollars/month), and 11 ± 4 years of formal education. Two third were from public hospitals and one third from private sector, 8% lived alone and 23% were unemployed. The median time to first medical contact was 30 (IQR 10-60) days, being the general practitioner (GP) the initial physician (52%), followed by orthopedist and rheumatologist (24% for both). The total time to see the rheumatologist was 90 (IQR 35-210) days, 32% of the patients delayed more than six months to contact a rheumatologist. Twenty five percent of patients had never been referred by their GPs, duplicating the access time to
rheumatologists [165 (IQR 30-365)] days. The median time to start a DMARD by the rheumatologist was 24 (IQR 6-365) days, which result on a total median time from onset of symptoms of five months. One quarter of patients took longer than 12 months to start a DMARD. Three health barriers were significantly associated with delay in consultation and treatment: geographical location, family and work responsibilities, and lack of economic resources. After adjusting for multiples confounders (health insurance, health care center, marital status, household members, comorbidities and age), the presence of health barriers was independently associated with increased delay to rheumatologist and initiation of a DMARD. In addition, being attended in early arthritis clinics were significantly associated to shorter delay in receiving DMARDs treatment. 

**Conclusion:** The delay in starting treatment with DMARDs was about 5 months. However, one-quarter of patients took longer than one year to start the treatment. The implementation of early arthritis clinics, a fast referral system and limitation of health barriers are good strategies to optimize the prompt treatment of the patients with RA.